Clinical Trials
23 trialsNCT01251874 2026-05-22
Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT01042379 2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT01351909 2026-04-13
Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT01366144 2026-04-13
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02595905 2026-04-08
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
National Cancer Institute (NCI)
Phase 2 Completed
NCT01149083 2025-08-15
Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01818063 2025-04-30
Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer
Thomas Jefferson University
Phase 2 Completed
NCT01009788 2025-03-14
ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer
Massachusetts General Hospital
Phase 2 Completed
NCT02163694 2025-02-19
A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer
AbbVie
Phase 3 Completed
NCT01618357 2024-05-22
Pre-Operative Radiation and Veliparib for Breast Cancer
Indiana University
Phase 1 Completed
NCT01506609 2021-10-25
Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer
AbbVie
Phase 2 Completed
NCT00892736 2018-06-29
Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy
National Cancer Institute (NCI)
Phase 1 Completed
NCT02210663 2018-05-07
A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced Solid Tumors
AbbVie
Phase 1 Completed
NCT01145430 2017-12-22
Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT01477489 2017-12-15
Veliparib With Radiation Therapy in Patients With Inflammatory or Loco-regionally Recurrent Breast Cancer
University of Michigan Rogel Cancer Center
Phase 1 Completed
NCT00526617 2017-11-21
A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients
AbbVie
Phase 1 Completed
NCT02009631 2017-11-20
A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors
AbbVie
Phase 1 Completed
NCT03032614 2017-10-10
Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
The University of Texas Health Science Center at San Antonio
Phase 2 Withdrawn
NCT01104259 2017-08-10
Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer
University of Washington
Phase 1 Completed
NCT01306032 2017-04-26
Phase II ABT-888 With Cyclophosphamide
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02033551 2016-09-27
A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors
AbbVie
Phase 1 Completed
NCT01281150 2015-05-25
Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT01233505 2014-04-02
Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Terminated